Navigation Links
Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
Date:5/9/2008

Boosts Cytopia's development of early pipeline cancer drug candidates

MELBOURNE, Australia, May 9 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) today announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of targeted therapeutics that is one of the fastest growing segments of the cancer drug market.

Cytopia will retain an option over exclusive commercialization rights for any drug candidates delivered by the collaboration. Should Cytopia choose not to exercise this option, Cancer Therapeutics may proceed with commercialization activities. In the event that all milestones to registration are successfully achieved, both Cancer Therapeutics and Cytopia will share in any partnering revenues, as well as royalty payments from a marketed drug.

Andrew Macdonald, CEO of Cytopia said, "Cytopia's drug discovery engine has generated many opportunities for novel cancer therapies and this innovative partnership gives us the freedom to focus investment on our later stage pipeline while still allowing our very early pipeline to move forward."

"Most importantly, the agreement leaves us with an option to capture the value upside for our investors if a new cancer drug is taken to market."

Under the terms of the collaboration, Cytopia has out-licensed specific proprietary technology to Cancer Therapeutics for an undisclosed kinase enzyme target with potential for treating metastatic cancers. Development of an inhibitor of this particular kinase could have blockbuster potential in the cancer market. Under the project plan,

Cancer Therapeutics will conduct and fund further development of the Cytopia compounds for at least two years. Cancer Therapeutics is a company, formed under the Australian Commonwealth Government's CRC scheme, to discover and develop new
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...wswire-USNewswire/ -- GlaxoSmithKline (GSK),in co...IG), a leading,academic breast cancer research net...east Cancer Cooperative Group (SOLTI), today annou...ll examine the role of TYKERB(R) in the,treatment ...atinib and/or,Trastuzumab Treatment Optimization) ...
(Date:5/9/2008)...ire-USNewswire/ -- Osteoarthritis is a,painful and...lmost 50,million people in the United States. It i...nts. The novel investigational pain medication,tap...ed significant relief,for patients with joint-dise...and with fewer gastrointestinal side effects than ...
(Date:5/9/2008)...re-FirstCall/ -- Ardea Biosciences, Inc.,(Nasdaq: ...velopment of,small- molecule therapeutics for the ..., including gout, today announced that John W. Bec...e and Operations and Chief,Financial Officer effec...f,directors shortly thereafter. The Company also r...
(Date:5/8/2008)...re-FirstCall/ -- DATATRAK International, Inc.,(Nas...cused on global,eClinical solutions for the clinic...esults for the first quarter of 2008., For the th...,approximately 41% to $2,088,000 and the Company r... share on both a basic and diluted basis. These,re...
Breaking Medicine Technology:TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Genmab Announces Results for the First Nine Months of 2007 1594 1Genmab Announces Results for the First Nine Months of 2007 1594 2Genmab Announces Results for the First Nine Months of 2007 1594 3Genmab Announces Results for the First Nine Months of 2007 1594 4Jefferson oncologists show focused radiation is effective as surgery against nerve tumor 5000 1Jefferson oncologists show focused radiation is effective as surgery against nerve tumor 5000 2Most Americans Have Poor Eye Q 4999 1Most Americans Have Poor Eye Q 4999 2Stanford researchers sniff out gene that gives dogs black fur 4996 1Stanford researchers sniff out gene that gives dogs black fur 4996 2Stanford researchers sniff out gene that gives dogs black fur 4996 3
...spinol,s (SP-233) Ability to Clear Brain,Plaque an...on , In Vivo ,Proof of Concept, Study Proposes Dir...ue and Memory Recovery , LAS VEGAS, July 10, 2007 ... (AMEX:LIV), a developer of innovative drugs,is p...(SP-233),efficacy in its ability to dramatically d...
...0, 2007 - Corgenix Medical,Corporation (OTC BB: CO...ted new clinical data demonstrating a significant ...patented AtherOx(TM),bio-markers and cardiovascula...gress of the International Society on Thrombosis a... released this week shows the association of antib...
Other Medicine Technology:Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 2Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able,to Heal From Alzheimer's Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4
(Date:5/12/2008).../PRNewswire-FirstCall/ - The Westaim Corporation,a...rch 31, 2008, it,recorded a net loss of $6.9 milli...on. In the same quarter last year, the company rec...hare, on revenues of $6.1 million., Income from c...ter,compared to $1.9 million in the same period la...
(Date:5/12/2008)...y 12, 2008) - Beta-blocker drugs may help prevent ...e the risk of death and major stroke, says a major...ious medical journal, The Lancet. , POISE is the...erative cardiac complications. POISE evaluated th...o patients around the time of surgery. , POISE ...
(Date:5/12/2008)... Are ,the Compassionate Heart, of System, WASHI...tment of,Veterans Affairs (VA), the nation,s large...es Week by honoring six of its top professionals.,... world-class health care,system," stated Secretary...deal of our reputation comes from the personal, on...
(Date:5/12/2008)...PRNewswire-FirstCall/ -- PAREXEL International,Cor...be presenting at the,Robert W. Baird 2008 Growth S...el, Senior Vice President and Chief Financial Offi...L at 10:05 a.m. EDT on Thursday, May 15,2008., A...le through the,"Investor Relations Webcasts" secti...
Breaking Medicine News(10 mins):Health News:Westaim announces 2008 first quarter results 2Health News:Westaim announces 2008 first quarter results 3Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 3Health News:PAREXEL International to Present at Robert W. Baird's 2008 Growth Stock Conference 2
...nt said Tuesday the rate of HIV/AIDS infections ha... a a major challenge in the country. The state-...rate fell from 6.1 percent in 2004 to the current ...ntry's nearly 35 million people. "Of notable sign...
...al Drug Helpline was launched by the Minister for ...lhi today on occasion of International Day Against...t this helpline would come handy to all of us part... She informed that the Ministry of Social Justice ...
...ealed that fruit, yoghurt, citric and soft drinks,...improper consumption and overuse may lead to devas...as tooth erosion, the break down of tooth structur...of acid on the teeth that leads to decay. Early d...
...sumer rights, the conservatives-dominated US Supre...uld be the ultimate fate of President George W. Bu...ppeal raising the issue of whether the medical equ...deral government may be sued under state law by pa...
Other Medicine News:Health News:Toll Free National Drug Helpline Launched 2Health News:Too Much of Acidic Foods can Cause Permanent Damage to Teeth 2Health News:US Supreme Court Could Protect Medical Equipment Manufacturers from Law Suits 2
...le pulse oximetry monitoring system compatible wit...nters. Extremely rugged and cost-effective.The BC...ly delivers pulse oximetry wherever spot-checking ...tpatient clinics and hospitals. In fact, its ergon...
The BCI 3180 Pulse Oximeter is a cost-effective, stand-alone monitor that delivers fast, reliable SpO 2 pulse rate and pulse strength measurements of patients from neonate to adult. This AC or batt
...git Finger Oximeter is a Pulse Oximeter and Sensor...e rate and pulse strength measurements on patients...large LED display, one button keypad and auto powe...it ideal for emergency, hospital or clinical envir...
...S. Food and Drug Administration (FDA) has granted ...s (IOL) for cataract patients with and without pre... apodized diffractive technology to give patients ... and distance) that greatly increases their indepe...
Medicine Products: